<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><description>BiG, Biologics Innovation Group. To nurture an Eco-system for Biologics innovation and imprint China on Global map.</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 22 Mar 2021 19:17:38 +0800</pubDate><image><url>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</url><title>BiG生物创新社 | wechat-feeds</title><link>http://MzkxNTA5NjM1OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>BiG春季聚会 | ADC热潮下的临床冷思考！</title><link>https://mp.weixin.qq.com/s/e003fKfdLfh5N5LDHLZ70Q</link><description></description><content:encoded><![CDATA[BiG春季聚会 | ADC热潮下的临床冷思考！]]></content:encoded><pubDate>Mon, 22 Mar 2021 17:48:41 +0800</pubDate></item><item><title>15款产品蜂拥入临床，PROTAC能否重塑小分子荣光？</title><link>https://mp.weixin.qq.com/s/cxnPmM4x2AZ3L5FA7tbKcw</link><description></description><content:encoded><![CDATA[15款产品蜂拥入临床，PROTAC能否重塑小分子荣光？]]></content:encoded><pubDate>Sun, 21 Mar 2021 09:38:37 +0800</pubDate></item><item><title>杨森新型TCB双抗：选择性招募γδT细胞亚群</title><link>https://mp.weixin.qq.com/s/Qw4d9O23oV_CHGP6zH8D_A</link><description></description><content:encoded><![CDATA[杨森新型TCB双抗：选择性招募γδT细胞亚群]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:30:59 +0800</pubDate></item><item><title>明星双抗，临床败北的启示！</title><link>https://mp.weixin.qq.com/s/0uLfi2BljwwiYKm01iqHhA</link><description></description><content:encoded><![CDATA[明星双抗，临床败北的启示！]]></content:encoded><pubDate>Fri, 19 Mar 2021 16:30:59 +0800</pubDate></item><item><title>科望智造！苏州工艺开发和中试生产基地正式落成！</title><link>https://mp.weixin.qq.com/s/HZJOcWCpvNCJz-_5v4_13Q</link><description></description><content:encoded><![CDATA[科望智造！苏州工艺开发和中试生产基地正式落成！]]></content:encoded><pubDate>Thu, 18 Mar 2021 15:51:09 +0800</pubDate></item><item><title>新江湖｜百英生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/4yyBZYk49yE5f1g7Fm7vkg</link><description></description><content:encoded><![CDATA[新江湖｜百英生物加入BiG会员机构！]]></content:encoded><pubDate>Thu, 18 Mar 2021 15:51:09 +0800</pubDate></item><item><title>T细胞导向疗法中双抗的空间因素</title><link>https://mp.weixin.qq.com/s/_sxKtTN3UixavRqG9Hr_gg</link><description></description><content:encoded><![CDATA[T细胞导向疗法中双抗的空间因素]]></content:encoded><pubDate>Tue, 16 Mar 2021 22:07:18 +0800</pubDate></item><item><title>新江湖｜邦耀生物加入BiG会员机构！</title><link>https://mp.weixin.qq.com/s/YZvtq0XG4nDhGE5DiMwL7g</link><description></description><content:encoded><![CDATA[新江湖｜邦耀生物加入BiG会员机构！]]></content:encoded><pubDate>Tue, 16 Mar 2021 22:07:18 +0800</pubDate></item><item><title>ADC市场竞逐：荣昌股票翻红，恒瑞、君实加速布局！</title><link>https://mp.weixin.qq.com/s/mZKGkUoq_uGbGPkrTBr8PQ</link><description></description><content:encoded><![CDATA[ADC市场竞逐：荣昌股票翻红，恒瑞、君实加速布局！]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:26:35 +0800</pubDate></item><item><title>SAR-T=CAR-T+双特异性抗体</title><link>https://mp.weixin.qq.com/s/dx5jt0zx2u_bkM1lG416ng</link><description></description><content:encoded><![CDATA[SAR-T=CAR-T+双特异性抗体]]></content:encoded><pubDate>Mon, 15 Mar 2021 07:26:35 +0800</pubDate></item><item><title>ADC迎来修罗场，PDC能否开辟新一春？</title><link>https://mp.weixin.qq.com/s/qQ79X1lZG12UB1MNHc3S2Q</link><description></description><content:encoded><![CDATA[ADC迎来修罗场，PDC能否开辟新一春？]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:32:35 +0800</pubDate></item><item><title>荐 | 60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！</title><link>https://mp.weixin.qq.com/s/RbbySGCVQjbximU2WBu7fA</link><description></description><content:encoded><![CDATA[荐 | 60+生物药企领袖聚首申城，研发动态、成果展示、合作案例，你想了解的单抗/双抗/ADC热点尽在BIT 2021！]]></content:encoded><pubDate>Fri, 12 Mar 2021 18:32:35 +0800</pubDate></item><item><title>新药上市后商业化有多难？</title><link>https://mp.weixin.qq.com/s/hha7mG2b1al13CN3txBCfw</link><description></description><content:encoded><![CDATA[新药上市后商业化有多难？]]></content:encoded><pubDate>Tue, 09 Mar 2021 22:43:39 +0800</pubDate></item><item><title>百奥赛图CD40抗体申报临床，后PD-1时代新君之争愈加激烈</title><link>https://mp.weixin.qq.com/s/f-sI4TJEun5KUiFhx5eTAw</link><description></description><content:encoded><![CDATA[百奥赛图CD40抗体申报临床，后PD-1时代新君之争愈加激烈]]></content:encoded><pubDate>Mon, 08 Mar 2021 17:11:03 +0800</pubDate></item><item><title>折戟路上的勇士！如何通过临床策略提升ADC成功率？</title><link>https://mp.weixin.qq.com/s/-wibTYu2ciHsWeoP7kE3TQ</link><description></description><content:encoded><![CDATA[折戟路上的勇士！如何通过临床策略提升ADC成功率？]]></content:encoded><pubDate>Fri, 05 Mar 2021 21:35:00 +0800</pubDate></item></channel></rss>